Highbridge Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Highbridge Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-400,000	Closed	-$3.84M	–	319
2024 Q4	$3.84M	Buy	+400,000	New	+$2.09M	0.14%	94

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Highbridge Capital Management's PSTX Position: Q1 2025 in Review

Highbridge Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 400,000 shares — an estimated $3.84M sold.

Highbridge Capital Management first reported a position in PSTX in Q4 2024 and held it in 1 quarter. The position peaked at $3.84M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Highbridge Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Highbridge Capital Management sold 400,000 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $3.84M.
Highbridge Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
Highbridge Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $3.84M in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Highbridge Capital Management's 13F filing for Q1 2025, filed 12 May 2025.